Isabelle Cohen
ID: UNCST-2025-R020977
|
Evaluating a “nearly free hour” for health centers in rural Uganda
REFNo: SS4726ES
This study has four specific objectives:
1. Evaluate the effects of a discounted, group visits window on ODH health centers, including how many ultrapoor patients visit the clinic during the discounted, group visits window.
2. Compare the discounted window to an all-day discount to understand whether a time-limited discount is (relatively) more effective at screening in the UP.
3. Document the extent to which the discounted window cannibalizes revenue by shifting patients from other times of day to the discounted window.
4. Analyze whether discounts encourage earlier treatment for mild/moderate malaria, and correspondingly reduce visits for severe malaria.
|
|
USA |
2026-01-27 19:41:22 |
2029-01-27 |
25000 |
The total set of districts includes ADJUMANI, AGAGO, ALEBTONG, AMOLATAR, AMURIA, AMURU, APAC, DOKOLO, GULU, KADERAMAIDO, KAGADI, KAKUMIRO, KASSANDA, KATAKWI, KIBAALE, KIKUUBE, KITGUM, KOLE, KUMI, KWANIA, LIRA, MASINDI, MUBENDE, NWOYA, OMORO, OTUKE, OYAM, PADER and SERERE.
The study sample focuses on villages in the catchment areas of existing ODH health clinics. We include villages that are not health clinic locations, from which more than a minimum number of patients visit ODH health clinics in an average week. We expect to sample roughly six villages per health clinic. All patients from a participating village who visit an ODH clinic included in the study will be considered part of the study.
|
Weiss Fund for Research in Development Economics, Princeton University’s Research Program in Development Economics and OneDay Health |
Social Science and Humanities |
Clinical Trial |
Non-degree Award |
|
Adeodata Rukyalekere Kekitiinwa
ID: UNCST-2019-R000799
|
Long-Acting Treatment in Adolescents (LATA); A randomized open-label 2-arm 96-week trial in virologically suppressed HIV-1-positive adolescents aged 12-19 years of age in Sub-Saharan Africa version 1.0 dated 01 December 2021.
REFNo: HS2515ES
• To evaluate an innovative and contemporary ART strategy in HIV- positive adolescents to provide choice for young people facing life-long treatment.
• To evaluate the virological efficacy, safety, acceptability, and quality-of-life of the dual long-acting injectable combination, cabotegravir and rilpivirine, antiretroviral therapy compared to continuous daily oral therapy with triple oral ART consisting of DTG with a backbone of tenofovir either as the TAF or TDF formulations, combined with either 3TC or FTC regimen, to optimize treatment for HIV-positive adolescents in sub-Saharan Africa.
|
Kampala, Mulago
|
Uganda |
2026-01-27 19:28:37 |
2029-01-27 |
170 |
Adolescents aged 12 to 19 years of age living with HIV-1 who are not pregnant or breastfeeding, and are virologically-suppressed (HIV-1 RNA <50 copies/mL) for at least one year, without any known history of treatment failure, on a 3-drug combination ART consisting of an anchor drug with a 2-drug nucleos(t)ide reverse transcriptase inhibitor (NRTI) backbone.
There will be no exceptions to eligibility requirements at the time of randomisation. Questions about eligibility criteria should be addressed prior to attempting to randomise the participant.
The eligibility criteria are the standards used to ensure that only medically appropriate patients are considered for this study. Patients not meeting the criteria should not join the study. For the
safety of the patients, as well as to ensure that the results of this study can be useful for making treatment decisions regarding other patients with similar diseases, it is important that no exceptions be made to these criteria for admission to the trial.
Participants will be considered eligible for enrolment in this trial if they fulfil all the inclusion criteria and none of the exclusion criteria as defined below.
INCLUSION CRITERIA
1. HIV-1-positive
2. Aged 12-19 years
3. Aware of HIV status
4. Body weight ≥35Kg
5. On ART consisting of 2NRTI and a third agent
6. On ART for ≥1 year with no previous regimen change for treatment failure*
7. Virologically suppressed with all HIV-1 RNA viral loads <50copies/mL¥ in the last 12 months up
to and including screening. Additionally, there must be one result <50copies/mL¥ at least 12 months
prior to screening and the viral load at trial screening must be <50 copies/mL
8. Written informed consent provided by participant (if aged 18 to 19 years) and/or carer/legal
guardian (if participant aged 12 to 17 years) as appropriate
9. Written informed assent in participants aged 12 to 17 years
10. Females who are sexually active must be willing to adhere to highly effective methods of
contraception⌂
EXCLUSION CRITERIA
1. Known HIV-2 positive
2. Females who are pregnant or breastfeeding
3. Females who plan to become pregnant during the trial follow-up or are sexually active and are
unwilling to avoid pregnancy for the duration of the trial
4. Moderate or high-risk score on the Columbia-Suicide Severity Rating Scale
5. Hepatitis B SAg positive
6. ALT ≥3 x upper limit of normal
7. On treatment for active TB
8. Known contraindication to receipt of dolutegravir, cabotegravir, rilpivirine, emtricitabine/
lamivudine and any formulation of tenofovir
9. Participants determined by the investigator to have a high risk of seizure, including those
with unstable or poorly controlled seizure disorder
10. Unwilling or contraindication to receiving injections
11. Contraindication to receiving injectable agents in the buttock area
12. Underlying medical condition (e.g. bleeding disorder; use of warfarin) that in the opinion of
the investigator precludes participation
13. Previous randomisation in the BREATHER Plus trial
|
University College London (UCL), UK and funded by the European and Developing Countries Clinical Trials Partnership |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Victoria Nankabirwa
ID: UNCST-2021-R011871
|
Relaxation Intervention to Improve Newborn Growth and Maternal Well-being
REFNo: HS6916ES
To examine the effect of the APRB on maternal outcomes such as stress, anxiety and depression.,To evaluate the effect of the adapted APRB on infant outcomes such as growth, feeding and adverse events.,To develop and adapt an audiorecording promoting relaxation during breastfeeding (APRB) for use among postpartum mothers Uganda.,
|
|
Uganda |
2026-01-19 15:24:38 |
2029-01-19 |
136 |
Adult women (18 years and above) and their infants.All sexes and tribes are eligible |
US National Institutes of Health |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
.jpg)
|
JOSELYN RWEBEMBERA
ID: UNCST-2021-R013915
|
A Non-Inferiority Trial of Stopping Penicillin in Early Rheumatic Heart Disease: GOAL-Stop
REFNo: HS6744ES
To explore if risk of progression differs between children who initially received 2 years of oral SAP as compared to 2 years of intramuscular SAP during the GOALIE trial. ,To determine in children with previously diagnosed mild RHD and echocardiographic stabilization after receiving SAP for at least 2 years, if stopping secondary antibiotic prophylaxis (SAP) is non-inferior to continuing SAP in preventing progression over the next 2 years. ,To determine in children with previously diagnosed mild RHD and echocardiographic normalization after receiving SAP for at least 2 years, if stopping SAP is non-inferior to continuing SAP for preventing progression over the next 2 years. ,To determine in children with previously diagnosed mild RHD and echocardiographic normalization or echocardiographic stability after receiving SAP for at least 2 years, if stopping SAP is non-inferior to continuing SAP for preventing progression by 4 years (2 years after SAP discontinuation). ,
|
|
Uganda |
2025-12-18 18:47:07 |
2028-12-18 |
992 |
Children and adolescents will be eligible for study participation if they (1) participated in the GOALIE Trial, (2) are found to have echocardiographic normalization or stable mild RHD at study completion, (3) are between the ages of 5-20 years at the time of enrollment. |
Thrasher Research Fund & Open Philanthropy |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Pauline Byakika-Kibwika
ID: UNCST-2019-R001206
|
A phase III, multi-country, randomized, placebo-controlled, double-blinded adaptive platform trial to assess the efficacy and safety of treatments for participants with Mpox virus disease
REFNo: HS6913ES
To evaluate the safety and efficacy, as assessed by mortality, hospitalization, complications, duration of symptoms of IP + SOC compared to placebo + SOC in participants with Mpox.,The primary objective is to evaluate the clinical efficacy, as assessed by time to lesion(s) resolution, of IP + Standard of Care (SOC) compared to placebo + SOC for participants with Mpox.,
|
Wakiso, kisubi
Mbarara, Mbarara
|
Uganda |
2025-12-18 18:34:19 |
2028-12-18 |
422 |
Participants fulfilling all the following inclusion criteria are eligible for the study:
1. Signed informed consent or assent for minor participants
2. Adults with positive mpox virus PCR confirmed within 7 days of D1and at least one
skin lesion:
- with known self-reported HIV positive with or without mucosal lesions
- Or
- Self-reported HIV negative or unknown HIV status with mucosal lesions
3. Children with positive mpox virus PCR confirmed within 7 days of D1 and at least
one skin lesion
4. Newborns with positive mpox virus PCR confirmed within 7 days of D1 and at least
one skin lesion
5. Specific to the BCV arm and matching placebo-Women participants of childbearing
potential willing to use condoms during treatment and for at least 2 months after the
last dose of BCV.
6. Specific to the BCV arm and matching placebo-Male participants with partners of
childbearing potential willing to use condoms during treatment and for at least 4
months after the last dose of BCV.
i. To protect women of a potential teratogenic treatment
ii. and anyhow for MSM (men who have sex with men to avoid sexual
transmission |
PANdemic Preparedness Platform for Health and Emerging Infections’ Response (PANTHER) |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
| View |
|
Sort By: |
|
|
|
| |
|
